SKYE BIOSCIENCE INC

DelveInsight's latest report identifies 18+ companies developing 20+ therapeutic candidates for open-angle glaucoma, with several treatments advancing through late-stage clinical trials.

Skye Bioscience's novel CB1 antibody nimacimab demonstrated 23.5% weight loss as monotherapy in diet-induced obesity models, comparable to effects seen with tirzepatide and monlunabant.

Eli Lilly's Zepbound demonstrated superior weight loss compared to Novo Nordisk's Wegovy in a head-to-head trial, with Zepbound users losing over 20% of body weight versus Wegovy's under 14%.

Skye Bioscience's CBeyond phase 2 trial of nimacimab, a CB1 inhibitor, has reached over 50% patient enrollment for overweight or obese participants.

Skye Bioscience has initiated a Phase 2 clinical trial for nimacimab, its investigational obesity treatment, marking a significant step in its development program.

• A new generation of CB1 receptor inhibitors is being developed by companies like Novo Nordisk, Corbus Pharmaceuticals, and Skye Bioscience for obesity treatment. • These new therapies aim to avoid the neuropsychiatric side effects seen in previous CB1 inhibitors by targeting peripheral receptors instead of those in the brain. • Early clinical trial results for drugs like nimacimab and monlunabant show promise in weight loss with varying degrees of neuropsychiatric side effects. • Combining CB1 inhibitors with GLP-1 drugs like Wegovy and Zepbound may offer enhanced weight loss and metabolic benefits, according to preclinical and early clinical data.